Curaleaf Holdings, Inc.

AI-generated fair value estimate for this company.

Method: EV/EBITDA approach: normalized EBITDA of ~$335M (≈26% margin on $1.276B TTM revenue, typical for scaled multi-state cannabis operators) at an 8.0x multiple = EV of $2.68B; less $938.4M net debt = $1.74B equity value / 755M shares = $2.31/share.

Reasoning: Curaleaf's GAAP net income and 'free cash flow' are structurally depressed by Section 280E (cannabis operators cannot deduct normal SG&A for federal tax purposes), so EV/EBITDA is the standard, more appropriate rigorous valuation method used across the cannabis MSO sector rather than a 280E-distorted FCF DCF.